-
Approximately A$10 million being raised to drive development of immuno-oncology and autoimmune programs and pursue regulatory pathways for lead product candidate, eftilagimod alpha
-
Capital raising comprised of:
-
A$4 million institutional placement of new ordinary shares to new Australian investors and existing Australian and foreign shareholders, including Platinum Investment Management Limited (trading as Platinum Asset Management), Australian Ethical Investment Limited and Altium Capital Management, LP
-
Fully underwritten entitlement offer to raise approximately A$6million
-
Strengthens the balance sheet ahead of the potentially pivotal AIPAC Phase IIb metastatic breast cancer trial readout expected in Q1 of calendar year 2020
-
Extends Immutep’s cash runway to the end of calendar year 2020
For further information please download the attached PDF:
Download this document
